GoodRx (NASDAQ:GDRX) Major Shareholder Francisco Partners Iv, L.P. Sells 471,975 Shares

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 471,975 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75. Following the sale, the insider owned 1,127,436 shares of the company’s stock, valued at $3,979,849.08. The trade was a 29.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68.

GoodRx Stock Performance

GoodRx stock opened at $3.45 on Friday. GoodRx Holdings, Inc. has a 12-month low of $1.77 and a 12-month high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. The business’s 50-day moving average price is $3.13 and its two-hundred day moving average price is $2.63. The stock has a market cap of $1.18 billion, a PE ratio of 86.27, a P/E/G ratio of 1.77 and a beta of 1.60.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same quarter in the previous year, the firm earned $0.09 earnings per share. The business’s quarterly revenue was down 1.3% on a year-over-year basis. As a group, analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on GDRX shares. TD Cowen boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Wells Fargo & Company increased their price target on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Citigroup raised their price objective on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. UBS Group boosted their price target on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Finally, Wall Street Zen raised GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.23.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock valued at $38,947,000 after purchasing an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. raised its stake in GoodRx by 4.0% during the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock worth $24,001,000 after buying an additional 184,734 shares during the last quarter. Renaissance Technologies LLC raised its stake in GoodRx by 1.5% during the first quarter. Renaissance Technologies LLC now owns 3,259,738 shares of the company’s stock worth $6,389,000 after buying an additional 48,800 shares during the last quarter. LSV Asset Management lifted its holdings in GoodRx by 20.0% in the fourth quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock valued at $7,658,000 after buying an additional 471,319 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in GoodRx by 6.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company’s stock valued at $7,183,000 after buying an additional 152,934 shares during the period. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.